Erdotin (erdosteine) / Recipharm, Alitair Pharma, Daewoong Pharma - LARVOL DELTA

Effectiveness of Erdosteine plus SITT (single inhaler triple therapy) in preventing exacerbation in comparsion to SITT in Non-smoker COPD: A muticenter study (ERS 2025) - No abstract available

Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Erdosteine's active metabolite MET-1 enhances antibiotic activity against S.aureus and P.aeruginosa in vitro (ERS 2025) - No abstract available

Preclinical • Respiratory Diseases

Interaction of Erdosteine with TrkA Signaling Pathways: Implications for Analgesia. (PubMed, Int J Mol Sci) - "This effect was inhibited by low millimolar concentrations of the two compounds, reaching a maximal inhibition (around 40%) after 24 h of exposure to 1 mM erdosteine, and then plateauing. These findings suggest that erdosteine can act as a TrkA antagonist, thus indicating that this drug may have potential as an analgesic via a novel non-opioid mechanism of action operating through NGF signaling inhibition at the level of TrkA."

Journal • Neuroblastoma • Oncology • Pain • Solid Tumor

An Unusual Cause of Hypoglycemia: Insulin Autoimmune Syndrome (ESPE-ESE 2025) - "We saw prescriptions for dexketoprofen, paracetamol, and erdosteine.​​ We adjusted the patient’s diet regimen and performed close blood sugar monitoring...The primary treatment for IAS is a diet consisting of low glycemic index foods. Additionally, steroids may be utilized as an adjunctive therapy."

Hypoglycemia • Immunology • Oncology • Solid Tumor

Antiviral Effect of Erdosteine in Cells Infected with Human Respiratory Viruses. (PubMed, Pathogens) - "The transcriptome analysis showed that erdosteine activated innate immune responses by stimulating overexpression of type I interferon and inflammasome pathways and modulated oxidative stress by inducing the modulation of oxidative stress and GSH pathways. These findings suggest that erdosteine may be a useful treatment for respiratory viral infections."

Journal • Colon Cancer • Colorectal Cancer • Infectious Disease • Influenza • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Respiratory Syncytial Virus Infections • Solid Tumor

Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study. (PubMed, Lung) - "Mucoactive treatment for two years reduced the number of COPD exacerbations (all, moderate) over five years of follow-up. The reduction in exacerbations was more pronounced in patients with cough or with stage 3‒4 COPD but was independent of the use of ICS."

Journal • Observational data • Real-world evidence • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Pulmonary Disease • Respiratory Diseases

Mucolytics for children with chronic suppurative lung disease. (PubMed, Cochrane Database Syst Rev) - "This systematic review is limited to a single small study, which we judged to be at high risk of bias. It remains uncertain whether regular nebulised hypertonic saline during a stable state reduces exacerbations or improves lung function. Further multi-centre, well-designed RCTs of longer duration that investigate various mucolytics are required to answer this important clinical question."

Clinical • Journal • Review • Bronchiectasis • Cough • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Non‐Cystic Fibrosis Bronchiectasis • Pulmonary Disease • Respiratory Diseases

Development of a rat airway organoids model for studying chronic obstructive pulmonary disease. (PubMed, Tissue Cell) - "Inflammatory markers responded differently, with ensifentrine and erdosteine significantly reducing cytokine levels. These results demonstrate that rat airway organoids replicate important aspects of human COPD pathology, thus providing an accessible, ethical, and clinically relevant alternative to human tissues and traditional animal models to enhance our understanding of COPD pathogenesis and evaluate potential treatments."

Journal • Preclinical • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Pharmacological profile of erdosteine - known molecule - new effects. (PubMed, Ceska Slov Farm) - "Its antioxidant and anti-inflammatory properties come to the fore, or antiviral properties associated with them, as well as the ability to reduce bacterial adhesion and increase the effects of some antibiotics. Erdostein represents a comprehensive therapeutic option both in the field of self-treatment of respiratory infections and in other respiratory diseases."

Journal • Review • Infectious Disease • Respiratory Diseases

Erdosteine: Reigniting a Thiol Mucolytic for Management of Chronic Obstructive Pulmonary Disease. (PubMed, J Assoc Physicians India) - "One of these agents which has reignited interest lately is erdosteine, with recent evidence demonstrating advantages over traditionally used N-acetylcysteine. In this review, we have summarized the key available evidence for the role of erdosteine in COPD, with takeaways on its place in therapy."

Journal • Review • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. (PubMed, Respir Investig) - "Mucolytics reduce exacerbations and hospitalizations in patients with stable COPD and have a safety profile comparable to that of placebo."

Journal • Retrospective data • Review • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

BRONCHIECTASIS AND POTENTIAL BENEFIT OF MUCOSAL VACCINE (CHEST 2024) - "The last infectious exacerbation was on January 2023 treated with ciprofloxacin 500 mgs bid for 2 weeks...We starting management based on dual bronchodilation (Tiotropium + Olodaterol), mucolytic (erdosteine) and immunotherapy with MV130, 2 sublingual shots OD for three months...By November 2023 she visited emergency department due to a new recurrence treated with amoxicillin/clavulanate... Clinical trials are needed to clear expectations of the mucosal vaccines in the bronchiectasis field."

Bronchiectasis • Chronic Cough • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Infectious Disease • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Respiratory Diseases

Improvement of Severe Scleroderma Cases with Lung and Heart Involvement Treated Using Methotrexat (EADV 2024) - "The therapy given is methotrexate 15 mg/week, folic acid 10 mg/week, mometasone furoate cream on the face, and clobetasol propionate ointment on other skin areas. Other treatments are salbutamol nebules, methylprednisolone 125 mg/day with tapering down, lansoprazole, erdosteine, furosemide, spironolactone and bisoprolol... T he patient is diagnosed with diffuse type scleroderma where there is involvement of major organs so that the patient has a poor prognosis. However, in the observations on patients for 1 month after therapy showed improvement of the condition of skin stiffness and reduced shortness of breath. MTX accompanied by systemic corticosteroids can be an inexpensive treatment option even in severe scleroderma conditions."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis • DHFR • TYMS

Erdosteine inhibits viral infection and modulates innate immunity and stress oxidative state in RSV-infected A549 cell (ERS 2024) - "Conclusions ERD modulates several molecular pathways involved in induction of anti-viral state. The upregulation of some ISGs and reduction of pro-inflammatory cytokines suggest ERD as adjuvant in respiratory viral infections."

Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • CASP4 • CCL2 • CXCL8 • DDX58 • GPX2 • ICAM1 • IFITM3 • IFNAR1 • IL1B • IL6 • ISG20 • SOD2

Effect of 5 years of treatment with mucoactive drugs on COPD exacerbations in the Czech Republic: a real-life study (ERS 2024) - "All patients had COPD with FEV1 ≤60% of predicted value, 81 of them were on treatment with thiol-based mucoactive drugs for 24 months (77 erdosteine, 4 N-acetylcysteine) and 371 patients were off mucoactive treatment for 24 months. The use of mucoactive treatment for two years showed a statistically significant reduction in the number of COPD exacerbations over the five years, for both all exacerbations and moderate exacerbations. The reduction in exacerbations was more pronounced in patients with cough and in patients with stage 3 to 4 COPD and was independent of the use of ICS."

Clinical • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Pulmonary Disease • Respiratory Diseases

The effectiveness of erdosteine in patients with COPD in combination with secondary bronchiectasis (ERS 2024) - "Conclusion. Added erdosteine to the basic therapy leads to a reduction in the duration of AE of COPD plus BE and also leads to a decrease in the levels of CRP, both at the onset of the remission phase and on the 30th day of therapy compared to patients who as basic therapy received LAMA/LABA/ICS"

Clinical • Combination therapy • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

REPEAT: Reducing Exacerbations in people with primary ciliary dyskinesia (PCD) using Erdosteine and Azithromycin Therapy (ANZCTR) - P3/4 | N=120 | Completed | Sponsor: Menzies School of Health Research | Recruiting ➔ Completed

Trial completion • Otorhinolaryngology • Respiratory Diseases

Effect of erdosteine on lipopolysaccharide-induced lung injury in mice (ERS 2024) - No abstract available

Preclinical • Respiratory Diseases

The Promising Effects of Erdosteine and Vitamin B in the Liver Ischemia/Reperfusion Model in Anesthetized Rats. (PubMed, Medicina (Kaunas)) - "These results suggest that the combination of vit B + Erd may be used to protect against the devastating effects of I/R injury. Our study needs to be confirmed by clinical studies with large participation."

Journal • Preclinical • Anesthesia • Cardiovascular • Reperfusion Injury • IL6 • TNFA

Ubiquitin-specific protease-7 promotes expression of airway mucin MUC5AC via the NF-κB signaling pathway. (PubMed, Heliyon) - "In addition, the expression of mucin 5AC (MUC5AC) was suppressed by the NF-κB inhibitor erdosteine. These findings suggest that USP7 stimulates the NF-κB signaling pathway, which promotes airway mucus hypersecretion. This study identifies one of the mechanisms regulating airway mucus secretion and provides a new potential target for its prevention and treatment."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases • Targeted Protein Degradation • MUC5AC • NFKBIA • USP7

Erdosteine in children and adults with bronchiectasis (BETTER trial): study protocol for a multicentre, double-blind, randomised controlled trial. (PubMed, BMJ Open Respir Res) - "We will publish the results and share the outcomes with the academic and medical community, funding and relevant patient organisations. ACTRN12621000315819."

Clinical protocol • Journal • Bronchiectasis • Pediatrics • Pulmonary Disease • Respiratory Diseases

Acute bronchitis - modern possibilities of mucactive therapy (PubMed, Ter Arkh) - "The findings expand our understanding of АВ in adults. New results have been obtained on the role of CRP, IL-6 and NO in exhaled air during АВ. The use of erdosteine was accompanied by a significant mucoactive effect in the form of a pronounced regression of cough in patients with АВ compared to the comparison group in shorter term."

Journal • Cough • Pulmonary Disease • Respiratory Diseases • CRP • IL6

Multiple green spectroscopic methods for erdosteine determination in bulk and dosage form with extensive greenness evaluation. (PubMed, Sci Rep) - "Furthermore, the eco-friendliness of the proposed methods was thoroughly checked using various greenness testing tools. Lastly, this work, not only presents highly sensitive, green, mix-and-read methods for ERD determination, but also, describes the determination of ERD spectrofluorimetrically for the first time in the literature."

Journal

Late Breaking Abstract - Erdosteine and its metabolite MET-1 modulate innate immunity and stress oxidative state in SARS-CoV-2 infection (ERS 2023) - "A decrease in expression level of IL-6 and IL-8 was reported as well as an overexpression of Oxidative Stress and Glutathione pathway (GPX2, GUSB, CAT, PRDX5) was observed. Conclusions Our data suggest that ERD can be effectively used in the treatment of viral infections thanks to its effect on improvement of immunity response, explained by activation of type 1 interferon and inflammasome pathways, and thanks to its antioxidant effect.; Public health; General respiratory patient care; Cell and molecular biology; Physiology; Imaging; Pulmonary function testing; Respiratory intensive care"

Late-breaking abstract • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CASP4 • CXCL8 • DDX58 • GPX2 • IFNA1 • IL6 • LRP4

Antiviral and anti-inflammatory effects of Erdosteine and MET-1 in SARS-CoV-2 in vitro infection (ERS 2023) - "Conclusions Erdosteine active metabolite (MET-1) has proven to have an antiviral effect, thus confirming the possibility to use this compound as an adjuvant agent against SARS-CoV-2. Further analysis is planned in order to understand the transcriptomic response of cells to the drugs and to evaluate the antiviral effect on other viruses, such as H1N1.; Pulmonary function testing; Respiratory intensive care; Public health; Epidemiology; General respiratory patient care; Cell and molecular biology"

Preclinical • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CXCL8 • IFNG • IL6